Prostate Cancer | Specialty

The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.

Identifying Factors That Limit Access to Prostate Cancer Therapy

February 2nd 2019

Jay H. Fowke, PhD, MPH, MS, chief, Division of Epidemiology, professor of preventive medicine, University of Tennessee Health Science Center, discusses factors that can lead to disparity in access to prostate cancer therapy.

Dr. Burgess on Understanding Molecular Subtypes of Prostate Cancer

January 31st 2019

Earle Burgess, MD, associate professor of medicine, Levine Cancer Institute, Atrium Health, discusses the importance of understanding the molecular subtypes of prostate cancer.

Apalutamide Improves Survival in Metastatic Castration-Sensitive Prostate Cancer

January 31st 2019

Apalutamide (Erleada) in combination with androgen deprivation therapy was found to significantly improve radiographic progression-free survival and overall survival versus placebo in patients with metastatic castration-sensitive prostate cancer.

Advancements Emerging in Nonmetastatic and mCRPC Paradigms

January 25th 2019

Tanya B. Dorff, MD, discusses landmark approvals in nonmetastatic castration-resistant prostate cancer and anticipated developments in the space.

Dr. Dorff on Choosing Between Therapies in Nonmetastatic CRPC

January 24th 2019

Tanya B. Dorff, MD, associate clinical professor, Department of Medical Oncology and Therapeutics Research, head, Genitourinary Cancers Program, City of Hope, discusses choosing between therapies in nonmetastatic castration-resistant prostate cancer.

Dr. Rayford on Racial Risk Stratification in Prostate Cancer

January 16th 2019

Walter Rayford, MD, PhD, MBA, a urologic oncologist with the Urology Group and associate professor of medicine at the University of Tennessee West Cancer Center, discusses a study aiming to refine racial risk stratification in prostate cancer.

Yu Previews Future of Castration-Naive Prostate Cancer

January 14th 2019

Evan Y. Yu, MD, discusses the available options for patients with metastatic castration-naïve prostate cancer.

Few Unanswered Questions Remain for Nonmetastatic Prostate Cancer

January 11th 2019

Harsha Ranganath, MD, discusses the current and future treatment of patients with nonmetastatic castration-resistant prostate cancer.

Radiation Oncologist Reflects on Traditional Treatment Modalities in Prostate Cancer

January 10th 2019

Holger L. Gieschen, MD, discusses the role of radiation therapy in prostate cancer and ongoing efforts to further refine this strategy.

Prostate Cancer Mortality Progress Stalls, Prompting Questions About PSA Policies

January 9th 2019

An analysis of prostate cancer trends adjusted for delays in reporting by stage of disease showed that incidence of late-stage disease increased from 2010 to 2014 after a decline in prostate-specific antigen use.

Assessing Risk Stratification Across Pivotal Prostate Cancer Trials

January 8th 2019

Daniel Vaena, MD, discusses the treatment of patients with metastatic castration-naïve disease and nonmetastatic castration-resistant prostate cancer, underscoring the importance of risk stratification in both settings.

Rucaparib Shows Encouraging Responses in BRCA+ mCRPC

January 8th 2019

Josep Piulats, MD, discussed the TRITON2 data and how rucaparib could shift treatment for these biomarker-specific patients with metastatic castration-resistant prostate cancer.

Radiotherapy Shows Benefit in Select Patients With Metastatic Prostate Cancer

January 4th 2019

Chris Parker, MD, discusses the clinical implications of STAMPEDE and how radiotherapy fits into the treatment paradigm for these patients.

Dr. Parker on Radiotherapy in Metastatic Prostate Cancer

January 3rd 2019

Chris Parker, MD, consultant clinical oncologist, The Royal Marsden NHS Foundation Trust, discusses the role of radiotherapy in patients with metastatic prostate cancer.

Study Refines Racial Risk Stratification in Prostate Cancer

January 2nd 2019

Walter Rayford, MD, PhD, MBA, discusses a race-based study in prostate cancer and how these results can drive treatment and diagnostic strategies.

Enzalutamide Improves Radiographic PFS in Metastatic Hormone-Sensitive Prostate Cancer

December 21st 2018

Enzalutamide plus androgen deprivation therapy (ADT) significantly improved radiographic progression-free survival compared with ADT alone.

Dr. Morris Discusses Biomarkers in Prostate Cancer

December 17th 2018

Michael J. Morris, MD, medical oncologist, clinical director, Genitourinary Medical Oncology Service, Division of Solid Tumor Oncology at Memorial Sloan Kettering Cancer Center, discusses biomarkers in prostate cancer.

Dr. Gieschen on Patient Selection for Radiation in Prostate Cancer

December 14th 2018

Holger L. Gieschen, MD, assistant professor, Department of Radiology, the University of Tennessee Health Science Center, radiation oncologist, West Cancer Center, discusses patient selection for radiation in the treatment of prostate cancer.

Enzalutamide/Radium-223 Combo Shows Potential in mCRPC

December 14th 2018

Benjamin L. Maughan, MD, PharmD, discusses the activity of the combination of radium-223 and enzalutamide in patients with metastatic castration-resistant prostate cancer.

Focal Therapy Evolves Into More Precise Treatment in Prostate Cancer

December 13th 2018

Historically, the management of localized prostate cancer has centered on removal or ablation of the entire gland with either extirpative surgery or radiation. However, the subsequent unacceptable adverse events profile can be devastating and life altering for many patients.